ClinicalTrials.gg
Sign In
RecruitingNCT07914270Updated Nov 3, 2026

Aquatic Power Training Dosing Strategies and Creatine Supplementation in Older Adults

An interventional study of RPE-1 Aquatic Power Training-Placebo and Time-Based Aquatic Power Training-Placebo in Aging, Supplementation and Exercise, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to participants aged 60 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Valencia · Not applicable, Interventional, and Prevention

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
60 Years to 99 Years
Sex
All
01

Study summary

This randomized controlled trial will investigate the effects of different aquatic power training dosing strategies and creatine supplementation on functional and multisystem adaptations in community-dwelling older adults.

Participants will be randomly allocated to one of five parallel groups: (1) aquatic power training regulated according to rating of perceived exertion during the first repetition (RPE-1) plus placebo; (2) aquatic power training using a conventional time-based dosing strategy plus placebo; (3) time-based aquatic power training plus creatine supplementation; (4) sedentary control plus placebo; or (5) sedentary control plus creatine supplementation.

The intervention will last 16 weeks. Aquatic training will be performed three times per week for approximately 60 minutes per session. Participants allocated to creatine supplementation will receive 3 g/day of creatine monohydrate, whereas the corresponding placebo groups will receive a visually indistinguishable placebo following the same supplementation schedule.

The primary outcomes will assess body composition, muscle strength, and functional capacity. Additional outcomes will examine bone health, cardiometabolic health, inflammatory and oxidative stress biomarkers, immune function, neurobiological and cognitive function, quality of life, sleep quality, psychological status, fatigue, and affective state.

Assessments will be performed before and after the 16-week intervention.

Read the detailed description

Participants will be randomly allocated to one of five parallel groups and will complete a 16-week intervention period. The study is designed to evaluate two complementary research questions: (1) whether an aquatic power training program regulated using rating of perceived exertion during the first repetition (RPE-1) produces different adaptations compared with a conventional time-based aquatic power training strategy; and (2) whether daily creatine supplementation enhances the adaptations associated with aquatic power training and/or modifies outcomes in sedentary older adults.

**Aquatic Power Training**

Participants allocated to either aquatic training condition will complete a 16-week supervised aquatic power training program consisting of three sessions per week, with each session lasting approximately 60 minutes.

The exercise program will focus on the development of muscular power using aquatic exercise. The two training conditions will follow the same overall intervention period and training frequency but will differ in the strategy used to regulate exercise dosage.

In the **RPE-1 aquatic power training condition**, exercise dosage will be regulated according to the participant's rating of perceived exertion during the first repetition (RPE-1). This strategy will be used to individualize and regulate the exercise stimulus during the training program.

In the **time-based aquatic power training condition**, exercise dosage will be prescribed using a conventional time-based strategy. Participants will therefore perform the aquatic power training according to the predefined temporal prescription rather than using RPE-1 to regulate exercise dosage.

Aquatic training sessions will be conducted under supervision at the Piscina Cubierta de Benimàmet (Fundación Deportiva Municipal, Valencia, Spain).

**Creatine and Placebo Supplementation**

Participants assigned to creatine supplementation will receive **3 g/day of creatine monohydrate** throughout the 16-week intervention. Supplementation will be taken daily, including non-training days, and no loading phase will be used.

Participants assigned to placebo supplementation will receive a visually indistinguishable placebo following the same daily supplementation schedule.

Creatine and placebo supplementation will be administered under double-blind conditions. Neither participants nor investigators responsible for supplementation administration will know the supplementation allocation until completion of the study.

**Study Groups**

Participants will be randomly allocated to one of the following five groups:

  1. **RPE-1 Aquatic Power Training + Placebo:** 16 weeks of aquatic power training, three sessions per week, with exercise dosage regulated according to RPE-1, combined with daily placebo supplementation.
  2. **Time-Based Aquatic Power Training + Placebo:** 16 weeks of aquatic power training, three sessions per week, using a conventional time-based dosing strategy, combined with daily placebo supplementation.
  3. **Time-Based Aquatic Power Training + Creatine:** 16 weeks of aquatic power training, three sessions per week, using the conventional time-based dosing strategy, combined with 3 g/day of creatine monohydrate.
  4. **Sedentary Control + Placebo:** Participants will not participate in the aquatic power training intervention and will receive placebo supplementation daily throughout the 16-week study period.
  5. **Sedentary Control + Creatine:** Participants will not participate in the aquatic power training intervention and will receive 3 g/day of creatine monohydrate throughout the 16-week study period.

Participants allocated to the sedentary control conditions will be instructed to maintain their usual lifestyle during the intervention period and not to initiate a structured moderate- or high-intensity strength or power training program.

**Assessment Schedule**

Outcome assessments will be performed before the intervention and immediately after completion of the 16-week intervention. Assessments will include body composition, muscle strength, functional capacity, bone metabolism, cardiometabolic health, inflammatory and oxidative stress biomarkers, immune function, neurobiological and cognitive function, quality of life, sleep quality, psychological status, fatigue, affective state, and clinical safety measures.

Questionnaires and cognitive assessments will be administered in person and distributed across two assessment sessions at each evaluation period to reduce participant fatigue.

Because of the nature of the exercise intervention, participants and personnel supervising the training cannot be blinded to the aquatic power training dosing strategy. However, outcome assessors and investigators responsible for statistical analyses will remain blinded to group allocation.

02

Conditions studied

  • Aging
  • Supplementation
  • Exercise

Browse trials for

Keywords

  • older adults
  • Nutritional Supplement
  • Aquatic training
  • Power training
  • Healthy aging
  • Non-Pharmacological intervention
  • Randomized controlled trial
03

In context

Motor Activity

9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 8,388 interventional studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.

Browse University of Valencia studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥60 years at enrollment.
  2. Community-dwelling and functionally independent in basic activities of daily living.
  3. Able to ambulate independently, with or without usual assistive devices, and able to safely perform the physical assessments included in the study.
  4. Clinically stable; participants with chronic diseases must have maintained stable pharmacological treatment for at least three months before the intervention.
  5. Not currently participating in a structured moderate- or high-intensity strength or power training program or another systematic supervised exercise program.
  6. Available and willing to participate throughout the 16-week intervention and complete all scheduled assessments.
  7. Willing to accept random allocation to any study group and creatine or placebo supplementation when applicable.
  8. Willing to maintain stable dietary habits throughout the intervention.
  9. Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled cardiovascular, respiratory, metabolic, neurological, or musculoskeletal disease contraindicating exercise or limiting safe participation.
  2. Unfavorable medical assessment for participation in supervised exercise.
  3. Uncontrolled hypertension at screening.
  4. Known kidney disease, renal failure, or impairment of renal function.
  5. Active liver disease or clinically relevant impairment of liver function.
  6. Active malignant neoplasm or current cancer treatment.
  7. Endocrine or metabolic disorders considered by the research team to substantially interfere with the study's primary outcomes.
  8. Current use, or use during the previous three months, of creatine or other supplements with potential ergogenic or anabolic effects.
  9. Pharmacological treatment considered likely to substantially modify the study's primary outcomes.
  10. Participation during the previous three months in a systematic moderate- or high-intensity strength or power training program.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Arm 1 - RPE-1 Aquatic Power Training + Placebo

    Participants will complete a 16-week aquatic power training program, three sessions per week, with each session lasting approximately 60 minutes. Training intensity will be regulated according to the participant's rating of perceived exertion during the first repetition (RPE-1). Participants will receive placebo supplementation daily throughout the 16-week intervention.

    Other: RPE-1 Aquatic Power Training-Placebo

  • Active comparator
    Arm 2 - Time-Based Aquatic Power Training + Placebo

    Participants will complete a 16-week aquatic power training program, three sessions per week, with each session lasting approximately 60 minutes. Exercise dosing will follow a conventional strategy based on work duration. Participants will receive placebo supplementation daily throughout the intervention.

    Other: Time-Based Aquatic Power Training-Placebo

  • Active comparator
    Arm 3 - Time-Based Aquatic Power Training + Creatine

    Participants will complete the same 16-week time-based aquatic power training program and will receive 3 g/day of creatine monohydrate throughout the intervention, including non-training days.

    Dietary Supplement: Time-Based Aquatic Power Training + Creatine

  • Placebo comparator
    Arm 4 - Sedentary Control + Placebo

    Participants allocated to the sedentary control group will not participate in the aquatic power training program and will receive placebo supplementation daily throughout the 16-week intervention.

    Dietary Supplement: Sedentary Control + Placebo

  • Experimental
    Arm 5 - Sedentary Control + Creatine

    Participants allocated to the sedentary control group will not participate in the aquatic power training program and will receive 3 g/day of creatine monohydrate throughout the 16-week intervention.

    Dietary Supplement: Sedentary Control + Creatine

Interventions

  • OtherRPE-1 Aquatic Power Training-Placebo

    Participants will complete a 16-week supervised aquatic power training program, consisting of three sessions per week, with each session lasting approximately 60 minutes. Exercises will be performed at maximal intended movement velocity. For each exercise, participants will perform 4 sets of 8 repetitions. Exercise intensity will be regulated using ratings of perceived exertion (RPE) obtained during the set. During the first repetition (RPE-1), the target RPE will be 4 for the active muscles or 3 for the overall body. By the last repetition of the set, the target RPE will be 6 for the active muscles or 5 for the overall body. Participants will perform active recovery for 120 seconds between sets and 90 seconds between exercises. This RPE-based dosing strategy will be used to individualize the aquatic power training stimulus according to each participant's perceived exertion while maintaining maximal intended movement velocity.

  • OtherTime-Based Aquatic Power Training-Placebo

    Participants will complete a 16-week supervised aquatic power training program, consisting of three sessions per week, with each session lasting approximately 60 minutes. Exercises will be performed at maximal intended movement velocity. The training structure will follow the same general protocol as the RPE-1 aquatic power training condition. However, instead of prescribing exercise volume according to a fixed number of repetitions regulated by RPE-1, participants will perform each exercise for an execution time equivalent to that required to complete the RPE-1 protocol. Participants will be instructed to perform the exercises at maximal intended movement velocity throughout the prescribed execution period. The maximu Participants will receive a placebo visually indistinguishable from the creatine supplement. The placebo will be administered daily throughout the 16-week intervention, including non-training days, following the same supplementation schedule as the creatine condition.

  • Dietary supplementTime-Based Aquatic Power Training + Creatine

    Participants will complete a 16-week supervised aquatic power training program, consisting of three sessions per week, with each session lasting approximately 60 minutes. Exercises will be performed at maximal intended movement velocity. The training structure will follow the same general protocol as the RPE-1 aquatic power training condition. However, instead of prescribing exercise volume according to a fixed number of repetitions regulated by RPE-1, participants will perform each exercise for an execution time equivalent to that required to complete the RPE-1 protocol. Participants will be instructed to perform the exercises at maximal intended movement velocity throughout the prescribed execution period. The maxi Participants will additionally receive 3 g/day of creatine monohydrate throughout the 16-week intervention. Participants will receive 3 g/day of creatine monohydrate for 16 weeks. Creatine will be administered daily, including non-training days, without a loading phase.

  • Dietary supplementSedentary Control + Placebo

    Participants allocated to this group will not participate in the aquatic power training intervention and will receive placebo supplementation daily throughout the 16-week study period. Participants will be instructed to maintain their usual lifestyle and habitual physical activity and not to initiate a structured moderate- or high-intensity strength or power training program during the intervention period. Participants will receive a placebo visually indistinguishable from the creatine supplement. The placebo will be administered daily throughout the 16-week intervention following the same supplementation schedule as the creatine condition.

  • Dietary supplementSedentary Control + Creatine

    Participants allocated to this group will not participate in the aquatic power training intervention and will receive 3 g/day of creatine monohydrate throughout the 16-week study period. Participants will be instructed to maintain their usual lifestyle and habitual physical activity and not to initiate a structured moderate- or high-intensity strength or power training program during the intervention period.

06

What researchers measure

Primary outcomes

  1. Change in Body Composition via Dual-Energy X-ray Absorptiometry (DXA)

    Whole body and segmental composition will be assessed through Dual-Energy X-ray Absorptiometry (DXA). Parameters analyzed will be: total and regional fat mass and lean mass and % of fat mass.

    Time frame: Pre and post-intervention of 16 weeks

  2. Change in handgrip strength

    Handgrip strength (Kg) will be assessed using hand-held dynamometry. Higher values indicate greater muscle strength

    Time frame: Pre and post-intervention of 16 weeks

  3. Change in lower limb Isokinetic muscle strength

    knee flexo-extension muscle strength will be assessed using an isokinetic dynamometer (Biodex®) at an angular velocity of 180°/s. Peak torque will be recorded in Newton-meters (Nm), with higher values indicating greater strength

    Time frame: Pre and post-intervention of 16 weeks

  4. Change in upper limb Isokinetic muscle Strength

    Elbow flexo-extension muscle strength will be assessed using an isokinetic dynamometer (Biodex®) at an angular velocity of 180°/s. Peak torque will be recorded in Newton-meters (Nm), with higher values indicating greater strength

    Time frame: Pre and post-intervention of 16 weeks

  5. Change in functional mobility and agility performance

    Functional mobility and agility will be assessed using the Timed Up and Go Test. The time required to stand from a chair, walk the standardized distance, turn, return, and sit down will be recorded in seconds. Lower values indicate better functional performance.

    Time frame: Pre and post-intervention of 16 weeks

  6. Change in lower body functional performance

    Lower-body functional capacity (resistance strength) will be assessed using the 30-Second Chair Stand Test. The number of complete sit-to-stand repetitions performed within 30 seconds will be recorded. Higher values indicate better functional performance.

    Time frame: Pre and post-intervention of 16 weeks

  7. Change in aerobic performance

    Functional aerobic capacity will be assessed using the 6-Minute Walk Test. The total distance walked during six minutes will be recorded in meters. Higher values indicate better functional capacity.

    Time frame: Pre and post-intervention of 16 weeks

Secondary outcomes

  1. Change in bone health (bone formation)

    Serum procollagen type I N-terminal propeptide (P1NP) will be measured as a marker of bone formation.

    Time frame: Pre and post-intervention of 16 weeks

  2. Change in bone health (bone resorption)

    Serum C-terminal telopeptide of type I collagen (β-CTX) will be measured as a marker of bone resorption

    Time frame: Pre and post-intervention of 16 weeks

  3. Change in cardiometabolic health (systolic blood pressure)

    Resting systolic blood pressure will be assessed and expressed in millimeters of mercury (mmHg), with lower values generally indicating lower cardiovascular risk.

    Time frame: Pre and post-intervention of 16 weeks

  4. Change in cardiometabolic health (diastolic blood pressure)

    Resting diastolic blood pressure will be assessed and expressed in millimeters of mercury (mmHg), with lower values generally indicating lower cardiovascular risk.

    Time frame: Pre and post-intervention of 16 weeks

  5. Change in metabolic biomarkers (total cholesterol)

    Total cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 16 weeks

  6. Change in metabolic biomarkers (HDL cholesterol)

    HDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 16 weeks

  7. Change in metabolic biomarkers (LDL cholesterol)

    LDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 16 weeks

  8. Change in metabolic biomarkers (Triglycerides)

    Triglycerides levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 16 weeks

  9. Change in metabolic biomarkers (fasting plasma glucose)

    Fasting plasma glucose concentration will be measured from blood samples collected after an overnight fasting period to assess changes in glucose homeostasis and metabolic state

    Time frame: Pre and post-intervention of 16 weeks

  10. Change in metabolic biomarkers (GLP-1 Concentration)

    Circulating glucagon-like peptide-1 (GLP-1) concentration will be measured from blood samples to assess changes in this gut-derived metabolic hormone involved in glucose regulation

    Time frame: Pre and post-intervention of 16 weeks

  11. Change in inflammation biomarkers (Interleukin-6 Concentration)

    Circulating interleukin-6 (IL-6) concentration will be measured from blood samples as a biomarker of systemic low-grade inflammation.

    Time frame: Pre and post-intervention of 16 weeks

  12. Change in inflammation biomarkers (Tumor Necrosis Factor-Alpha Concentration)

    Circulating tumor necrosis factor-alpha (TNF-α) will be measured from blood samples as a biomarker of systemic low-grade inflammation.

    Time frame: Pre and post-intervention of 16 weeks

  13. Change in Oxidative stress biomarkers (F2-Isoprostane Concentration)

    F2-isoprostanes will be measured from blood samples as biomarkers of oxidative stress and lipid peroxidation.

    Time frame: Pre and post-intervention of 16 weeks

  14. Change in Oxidative stress biomarkers (Glutathione Peroxidase Activity)

    Glutathione peroxidase (GPx) activity will be measured from blood samples as a marker of antioxidant defense.

    Time frame: Pre and post-intervention of 16 weeks

  15. Change in Immune system (Total Leukocyte Count)

    Total circulating leukocyte count will be measured from peripheral blood samples to assess changes in overall immune cell status

    Time frame: Pre and post-intervention of 16 weeks

  16. Change in Immune system (Neutrophil Count)

    Circulating neutrophil count will be measured from peripheral blood samples to assess changes in the neutrophil component of the immune response

    Time frame: Pre and post-intervention of 16 weeks

  17. Change in Immune system (Lymphocyte Count)

    Circulating lymphocyte count will be measured from peripheral blood samples to assess changes in the lymphocyte component of immune function

    Time frame: Pre and post-intervention of 16 weeks

  18. Change in Immune system (Monocyte Count)

    Circulating monocyte count will be measured from peripheral blood samples to assess changes in this component of the innate immune system

    Time frame: Pre and post-intervention of 16 weeks

  19. Change in Immune system (Eosinophil Count)

    Circulating eosinophil count will be measured from peripheral blood samples to assess changes in this leukocyte population

    Time frame: Pre and post-intervention of 16 weeks

  20. Change in Immune system (Basophil Count)

    Circulating basophil count will be measured from peripheral blood samples to assess changes in this leukocyte population

    Time frame: Pre and post-intervention of 16 weeks

  21. Change in Immune system (Platelet Count)

    Circulating platelet count will be measured from peripheral blood samples to assess changes in platelet levels

    Time frame: Pre and post-intervention of 16 weeks

  22. Change in Immune system (Neutrophil-to-Lymphocyte Ratio)

    The neutrophil-to-lymphocyte ratio (NLR) will be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. NLR will be used as an integrated hematological marker of systemic inflammatory and immune status.

    Time frame: Pre and post-intervention of 16 weeks

  23. Change in Immune system (Systemic Immune-Inflammation Index )

    The Systemic Immune-Inflammation Index (SII) will be calculated from peripheral blood platelet, neutrophil, and lymphocyte counts as an integrated marker of systemic immune-inflammatory status.

    Time frame: Pre and post-intervention of 16 weeks

  24. Change in Neurobiological function (Brain-Derived Neurotrophic Factor concentration)

    Circulating brain-derived neurotrophic factor (BDNF) concentration will be measured from blood samples to assess changes in a neurotrophic factor involved in neuronal function and neuroplasticity .

    Time frame: Pre and post-intervention of 16 weeks

  25. Change in Cognitive function (Trail Making Test Part A Completion Time)

    Cognitive performance will be assessed using the Trail Making Test Part A (TMT-A), which primarily evaluates visual attention, processing speed, and visuomotor tracking. Participants will be instructed to connect numbered targets sequentially as quickly and accurately as possible. Completion time will be recorded in seconds, with lower completion times indicating better performance.

    Time frame: Pre and post-intervention of 16 weeks

  26. Change in Cognitive function (Trail Making Test Part B Completion Time)

    Executive and attentional performance will be assessed using the Trail Making Test Part B (TMT-B), which requires participants to alternate sequentially between numbered and lettered targets. The test primarily assesses cognitive flexibility, set-shifting, divided attention, and executive function. Completion time will be recorded in seconds, with lower completion times indicating better performance.

    Time frame: Pre and post-intervention of 16 weeks

Other outcomes

  1. Change in WHOQOL-OLD Score

    Quality of life in older adults will be assessed using the World Health Organization Quality of Life-OLD (WHOQOL-OLD) questionnaire, which evaluates relevant dimensions of quality of life specifically related to older populations. Changes in questionnaire scores will be used to assess the effect on perceived quality of life.

    Time frame: Pre and post-intervention of 16 weeks

  2. Change in Health-Related Quality of Life Assessed by the EQ-5D-5L

    Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The instrument evaluates health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Changes in EQ-5D-5L health status will be used to assess the effect on perceived health-related quality of life.

    Time frame: Pre and post-intervention of 16 weeks

  3. Change in Pittsburgh Sleep Quality Index Score

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), which evaluates different aspects of sleep over the preceding month. Changes in the global PSQI score will be used to assess sleep quality, with higher scores indicating poorer sleep quality

    Time frame: Pre and post-intervention of 16 weeks

  4. Change in Depressive symptoms

    Depressive symptoms will be assessed using the 9-item Patient Health Questionnaire (PHQ-9). Changes in the total score will be used to assess depressive symptom severity, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Pre and post-intervention of 16 weeks

  5. Change in Fatigue

    Fatigue will be assessed using the 10-item Fatigue Assessment Scale (FAS). Each item is rated on a five-point response scale ranging from 1 (never) to 5 (always). Changes in the total FAS score will be used to assess perceived fatigue, with higher scores indicating greater fatigue.

    Time frame: Pre and post-intervention of 16 weeks

  6. Change in Affective State

    Positive affect will be assessed using the Positive Affect subscale of the Positive and Negative Affect Schedule (PANAS). The PANAS comprises 20 affect-related items rated on a five-point response scale. Changes in the Positive Affect subscale score will be used to assess changes in positive emotional state, with higher scores indicating greater positive affect.

    Time frame: Pre and post-intervention of 16 weeks

  7. Change in Serum Creatinine

    Serum creatinine concentration will be assessed as a clinical safety marker related to renal function.

    Time frame: Pre and post-intervention of 16 weeks

  8. Change in Alanine Aminotransferase

    Serum alanine aminotransferase (ALT) concentration will be assessed as a clinical safety marker related to liver function.

    Time frame: Pre and post-intervention of 16 weeks

  9. Change in Aspartate Aminotransferase

    Serum aspartate aminotransferase (AST) concentration will be assessed as a clinical safety marker related to liver function.

    Time frame: Pre and post-intervention of 16 weeks

  10. Incidence of Adverse Events

    Adverse events potentially associated with the aquatic exercise intervention or creatine/placebo supplementation will be recorded and clinically evaluated throughout the intervention period.

    Time frame: Throughout the 16-week intervention.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 6 months is below that.

Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 3, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
May 15, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07914270
Lead sponsor
University of Valencia
Collaborators
CIAICO/2023/056 Project (Generalitat Valenciana AICO Grants), Generalitat Valenciana
Responsible party
Juan C. Colado (Chaired Full Professor of Physical Education, University of Valencia) — Principal investigator
First posted
Nov 3, 2026
Start date
Oct 15, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Juan Carlos Colado Sánchez, Chair full professor
Contact
juan.colado@uv.es
(9639) 83470

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Motor Activity →

Other studies from this sponsor

University of Valencia →

Start the discussion